公开(公告)号：US20210115016A1

公开(公告)日：2021-04-22

申请号：US16631738

申请日：2018-07-18

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Muzaffar ALAM ,  Hilary Plake BECK ,  Michael Patrick DILLON ,  Marcos GONZALEZ-LOPEZ ,  Alice Chen RICO ,  James Clifford SUTTON, Jr.

IPC: C07D401/12 ,  C07D403/12 ,  C07D401/14 ,  C07D471/04 ,  C07D487/04 ,  C07D215/12 ,  C07D217/18 ,  C07D405/12 ,  C07D413/12 ,  C07D413/14

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.

公开(公告)号：US20210002297A1

公开(公告)日：2021-01-07

申请号：US17023980

申请日：2020-09-17

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Muzaffar ALAM ,  Hilary Plake BECK ,  Michael Patrick DILLON ,  Marcos GONZALEZ-LOPEZ ,  James Clifford SUTTON, JR.

IPC: C07D498/04 ,  A61P35/00 ,  C07D471/04 ,  C07D487/04 ,  C07D491/107 ,  C07D513/04 ,  C07D519/00

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.

公开(公告)号：US20230303556A1

公开(公告)日：2023-09-28

申请号：US18188278

申请日：2023-03-22

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Paul A. BARSANTI ,  Michael Patrick DILLON ,  Firoz Ali JAIPURI ,  Ying-Zi XU ,  Xin LINGHU ,  Monah ABED

IPC: C07D417/14 ,  A61P35/00

CPC classification number: C07D417/14 ,  A61P35/00

Abstract: Provided herein are compounds of Formula (I):




or a pharmaceutically acceptable salt thereof. The provided compounds are useful Poly ADP-ribose glycohydrolase (PARG) inhibitors. Additional utilities and advantages are described herein.

公开(公告)号：US20240269143A1

公开(公告)日：2024-08-15

申请号：US18565392

申请日：2022-06-01

Applicant: IDEAYA BIOSCIENCES, INC. ,  GlaxoSmithKline Intellectual Property (No.4) Limited

Inventor： Michael Patrick DILLON ,  Marcus Michael FISCHER ,  Kimberline Yang GERRICK ,  Jenny Laraio ,  Helai Mohammad ,  Kimberly Smitheman

IPC: A61K31/519 ,  A61K31/415 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K31/415 ,  A61P35/00

Abstract: Provided herein is a combination therapy and methods of using such combination therapy to treat diseases or disorders associated with MAT2A and/or Type I PRMT.

公开(公告)号：US20230303510A1

公开(公告)日：2023-09-28

申请号：US18006991

申请日：2021-07-28

Applicant: Ideaya Biosciences, Inc.

Inventor： Hilary Plake BECK ,  Michael Patrick DILLON ,  Brian Thomas JONES ,  Luisruben Padilla MARTINEZ

IPC: C07D401/04 ,  C07D207/09 ,  C07D413/04 ,  C07D401/14 ,  C07D405/14 ,  C07D403/04

CPC classification number: C07D401/04 ,  C07D207/09 ,  C07D413/04 ,  C07D401/14 ,  C07D405/14 ,  C07D403/04

Abstract: The present invention relates to methods for treating bacterial infections caused by or
Provided and set forth herein are certain cyclized acetamido derivatives that are DNA Polymerase Theta (Polθ) inhibitors of Formula (I) and Formula II.




Also, provided are pharmaceutical compositions comprising such compounds, and methods of treating diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers, using such compounds and pharmaceutical compositions.

公开(公告)号：US20230039955A1

公开(公告)日：2023-02-09

申请号：US17853647

申请日：2022-06-29

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Muzaffar ALAM ,  Hilary Plake BECK ,  Michael Patrick DILLON ,  Marcos GONZALEZ-LOPEZ ,  James Clifford SUTTON, JR.

IPC: C07D498/04 ,  A61P35/00 ,  C07D471/04 ,  C07D487/04 ,  C07D491/107 ,  C07D513/04 ,  C07D519/00

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2e and R2d have the meanings provided in the specification.

公开(公告)号：US20220227780A1

公开(公告)日：2022-07-21

申请号：US16648865

申请日：2018-09-25

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Hilary Plake BECK ,  Leah Brigit CLEARY ,  Michael Patrick DILLON ,  Marcos GONZALES-LOPEZ ,  Luis Ruben P. MARTINEZ ,  James Clifford SUTTON

IPC: C07D495/04 ,  A61K31/4365 ,  C07D519/00 ,  A61K31/437 ,  A61K31/5025 ,  A61K31/519 ,  A61P35/00

Abstract: Compounds are provided having Formula (I): wherein R, R1, Cyc and A have the meanings provided herein. The compounds have utility in the treatment of diseases, either alone or in combination with other agents.

公开(公告)号：US20190270754A1

公开(公告)日：2019-09-05

申请号：US16268444

申请日：2019-02-05

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Muzaffar ALAM ,  Hilary Plake BECK ,  Michael Patrick DILLON ,  Marcos GONZALEZ-LOPEZ ,  James Clifford SUTTON, JR.

IPC: C07D498/04 ,  A61P35/00 ,  C07D487/04 ,  C07D491/107 ,  C07D513/04 ,  C07D471/04

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.

公开(公告)号：US20240173326A1

公开(公告)日：2024-05-30

申请号：US18405638

申请日：2024-01-05

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Michael Patrick DILLON ,  Claire L. NEILAN ,  Marcus Michael FISCHER ,  Kimberline Yang GERRICK

IPC: A61K31/519 ,  A61K31/502 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K31/502 ,  A61P35/00

Abstract: Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatment of a variety of cancers, including solid tumors. The combination product is useful for the treatment of any number of MAT2A-associated and/or PRMT-associated diseases.

公开(公告)号：US20240108626A1

公开(公告)日：2024-04-04

申请号：US18501729

申请日：2023-11-03

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Michael Patrick DILLON ,  Claire L. NEILAN ,  Marcus Michael FISCHER ,  Kimberline Yang GERRICK

IPC: A61K31/519 ,  A61K31/502 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K31/502 ,  A61P35/00

Abstract: Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatment of a variety of cancers, including solid tumors. The combination product is useful for the treatment of any number of MAT2A-associated and/or PRMT-associated diseases.